Patent · US Active

Biocompatible polycaprolactone fumarate formulations

US10426867B2 · kind B2 · utility

0Cited by

1References

10Claims

0Family size

Assignee

Mayo Foundation for Medical Education and Research · US

Inventors

Michael B. Runge · Pine Island, US
Michael J. Yaszemski · Rochester, US

Key dates

Filing date	Apr 4, 2012
Grant date	Oct 1, 2019
Priority date	—
Expiry date	Apr 4, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC08G63/60
WIPO fieldMedical technology
WIPO sectorInstruments

Abstract

A polycaprolactone fumarate polymer useful as a matrix material for a biocompatible scaffold for tissue engineering applications is disclosed. The polycaprolactone fumarate polymer can be prepared by reacting caprolactone with an alkane polyol to prepare a polycaprolactone precursor, and then reacting the polycaprolactone precursor with fumaric acid or a salt thereof to prepare the polycaprolactone fumarate polymer. The use of an alkane diol, such as 1,2-propanediol, provides a linear polycaprolactone diol precursor. The use of an alkane triol, such as glycerol, provides a branched polycaprolactone triol precursor. The biocompatible polycaprolactone fumarate formulation releases no diethylene glycol or other undesirable byproducts during degradation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.